Clinical Trial

Efficacy of Camel Whey Protein and Camel Whey Protein Nanoparticles for Treating Intra-bony Periodontal Defects

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 13, 2026 (before its estimated July 24, 2026 completion). Its status may not reflect the trial's current state.
Summary
Intraosseous bone defects (IOBDs) are a significant challenge in the treatment of periodontal disease. Several bone graft materials can be used for bone defect regeneration. Camel whey protein (CWP) has emerged as a promising alternative due to its unique properties, including: High biological value containing essential amino acids, anti-inflammatory, antioxidant and immunomodulatory effects. However, the therapeutic application of CWP for bone regeneration can be limited by its solubility and bioavailability . Nanoparticles offer a novel approach to enhance drug delivery and improve therapeutic efficacy. Introduction of bone grafts in the form of nanoparticles was found to improve the bioactivity and biocompatibility of artificial bone graft. Nanoparticles (NPs) can efficiently enter biological organisms due to their very tiny size. The ability of NPs to easily pass through even the smallest blood capillaries and escape being phagocytized due to their small size (1-100 nm) extends their plasma half-life and permits a more progressive release of the medication. Nanoparticles have quicker absorption and a relatively greater drug loading arise from interactions at the surface. NPs increased antibacterial action may be attributed to their huge surface area and high charge density, which allows them to interact with the negatively charged surface of bacterial cells
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-13.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-02-12
Trial Details
NCT Number NCT07358104
Lead Sponsor Kafrelsheikh University
Conditions Periodontal Diseases, Periodontal Attachment Loss
Enrollment 44 participants
Start Date 2026-01-06
Primary Completion 2026-07-24 (estimated)
Study Completion 2026-08-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-13